Clinical Trials Logo

Clinical Trial Summary

Recent studies estimated that 15 to 20% of all cancers in humans are associated with viruses. Among oral cancer about 90% are oral squamous cell carcinomas (OSCC). Alcohol and tobacco consumption have been recognized for years as the main risk factors for development of OSCCs. However, 10 to 20% of patients suffering from OSCCs are non-smokers and/ or non-drinkers. Consequently, the hypothesis of another agent responsible has risen. Indeed, several studies have suggested the possibility that a virus could be associated with or be a causal agent of OSCC. The first objective is to detect and characterize the presence of infectious agent (mostly virus) transcripts in pre-malignant or malignant tumours from patients with OSCCs.The secondary objectives are (i) to associate and (ii) if possible define a causality link between these agents and a subset of potentially malignant disorders and/or OSCCs.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01636544
Study type Interventional
Source Institut Pasteur
Contact
Status Completed
Phase N/A
Start date June 15, 2012
Completion date January 31, 2016

See also
  Status Clinical Trial Phase
Recruiting NCT05540899 - Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer Phase 1
Completed NCT01108042 - TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer Phase 1/Phase 2
Not yet recruiting NCT06380686 - Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Active, not recruiting NCT03721757 - CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer Phase 2
Completed NCT02873819 - Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity Phase 2
Active, not recruiting NCT04387682 - Myeloid-derived Suppressor Cells (MDSCs) in OSCC Patients N/A
Completed NCT01321892 - Ex Vivo Multimodal Imaging of Upper Aerodigestive Epithelium N/A
Not yet recruiting NCT05608369 - Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC Phase 2
Withdrawn NCT04831450 - Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) Phase 2
Recruiting NCT04191460 - Fluorescence-guided Surgery Using cRGD-ZW800-1 in Oral Cancer Phase 2
Recruiting NCT06030440 - De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck Phase 2/Phase 3
Terminated NCT01077869 - A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis Phase 1
Completed NCT02609386 - IRX-2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity Phase 2
Not yet recruiting NCT05452408 - Antitumor-B KAC PK Study Phase 1
Not yet recruiting NCT03364166 - Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma N/A
Terminated NCT02331875 - Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity Phase 1/Phase 2
Completed NCT01265849 - Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity Phase 3
Active, not recruiting NCT03370276 - Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 1/Phase 2
Completed NCT03575598 - Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study Early Phase 1
Active, not recruiting NCT03459729 - Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer Early Phase 1